MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Increased Survival In Metastatic Colorectal Cancer

Back to colon cancer blog Blogs list Cancer blog  


Subscribe To Colon Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Increased Survival In Metastatic Colorectal Cancer

Increased Survival In Metastatic Colorectal Cancer
A phase III trial of 1,298 colorectal cancer patients has observed that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, as per an international team of researchers.

The Erbitux Plus Irinotecan in Colorectal Cancer (EPIC) study looked at survival in metastatic colorectal cancer patients who had already shown resistance to conventional therapies. The research was presented today at the 2007 Annual Meeting of the American Association for Cancer Research.

By the end of the study, a significantly larger number of patients who received the combination of cetuximab, an antibody against the epidermal growth factor and irinotecan, an enzyme-inhibiting cancer drug, survived without their cancers progressing further. The tumor response rate in this group was also significantly higher. The study was sponsored, in part, by Bristol-Myers Squibb and Merck KGaA.

"Patients who received both cetuximab and irinotecan experienced longer periods of time spent, on average, without further progression of the disease," said Alberto F. Sobrero, M.D., of the San Martino Hospital's Department of Medical Oncology in Genoa, Italy. "From a patient perspective, any improvement in progression-free survival, as well as tumor shrinkage, is worthwhile. These data confirm that, despite a moderate increase in side effects, cetuximab is a key therapeutic agent in the optimal therapy of advanced colorectal cancer".

The EPIC trial was designed to study the overall survival in patients treated with both cetuximab and irinotecan, with secondary objectives that include response rate and progression-free survival. Patients eligible in the trial had to have shown resistance to the drug oxaliplatin, a platinum-based treatment usually used in the therapy of colorectal cancer.

The trial participants, enrolled from cancer centers across Europe, Australia and the United States, were primarily male (62.9%) and Caucasian (91.6 %), with a median age of 62. The patients were randomly placed in groups to receive irinotecan every three weeks or irinotecan plus cetuximab every three weeks, and were treated until their disease progressed.

Once the cancer progressed, the scientists stopped study therapy, and further therapy was at the discretion of the patient's physician. As per Sobrero, 16 percent of patients who received both medications responded to the therapy versus four percent of patients who received irinotecan alone.

Despite these positive findings, there was no difference in overall survival between the two arms in this study. Nearly half of the patients, who were initially treated with irinotecan only, were given cetuximab when their cancers progressed. Therefore, a number of patients in both arms actually received the same therapy, which the scientists say could explain the lack of difference in overall survival between the two arms.

The EPIC scientists reported a comparative increase in side effects for the patients who received the combination treatment, including fatigue, diarrhea and an acne-like rash previously linked to cetuximab.


Posted by: Sue    Source




Did you know?
A phase III trial of 1,298 colorectal cancer patients has observed that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, as per an international team of researchers. The Erbitux Plus Irinotecan in Colorectal Cancer (EPIC) study looked at survival in metastatic colorectal cancer patients who had already shown resistance to conventional therapies. The research was presented today at the 2007 Annual Meeting of the American Association for Cancer Research.

Medicineworld.org: Increased Survival In Metastatic Colorectal Cancer

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.